Nexstar Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Somalogic, Incorporated

University Research Corporation

Other

Proligo, LLC

Nexstar Pharmaceuticlas, Inc.

Schering Aktiengesellschaft

Somalogic Operating Co., Inc.

Glead Sciences, Inc.

Schering Akiengesellschaft

Nexstar Pharmacueticals, Inc.

Larry M Gold

Nebojsa Janjic

Sumedha D Jayasena

Dominic Zichi

Bruce Eaton

Daniel J Schneider

Craig Tuerk

Sheri K Wilcox

Kirk B Jensen

Andrew Stephens

Nikos C Pagratis

Diane Tasset

David H Parma

Jonathan Drew Smith

Brian James Hicke

Drew Smith

Chris Bock

Paul J Schmidt

Gary P Kirschenheuter

Steven Ringquist

Matthew Wecker

Wolfgang A Pieken

Michael Willis

Tad H Koch

Hang Chen

Dan Nieuwlandt

Gregory Biesecker

Kevin N Morris

Dan W Drolet

Philippe Bridonneau

Bruce E Eaton

Marty Stanton

Chandra Vargeese

Robert Delmar Jenison

Daniel W Drolet

Stanley C Gill

Patrick Nikita Allen

Steve Creighton

Brent Atkinson

Ulrich Speck

Thale Jarvis

Stephen L Warren

Dom Zichi

Daniel T Nieuwlandt

Ken Davis

James R Heil

Todd Gander

Michael Lochrie

Joseph S Heilig

Greg Biesecker

Alex A Stewart

Glenn P Vonk

Urs Ochsner

Douglas P Malinowski

Paul G Schmidt

Louis S Green

Stephan Kraemer

Jeffrey D Carter

Shashi Gupta

David Pribnow

Juli Feigon

Dan J Schneider

Torsten Walter Wiegand

Dan T Nieuwlandt

Ted Tarasow

Donald Burke

Penelope J Toothman

Judy Ruckman

Timur Shtatland

Brenda Javornik

J Bruce Pitner

Martin Stanton

Kurt Vagle

Kenneth A Davis

Rachel M Ostroff

James Bruce Pitner

Jeff Carter

Evaldas Katilius

Danny P McGee

Deborah Ayers

Alex A E Stewart

Glenn Sanders

Edward N Brody

Michael Riel-Mehan

Alan J Korman

Sumedha Javasena

Barry Polisky

Chad Greef

Ross S Rabin

Sumeda Jayasena

Michael A Lochrie

Bruce Beutel

Rebecca Vanderslice

Ken Hill

Mace Golden

Ross Rabin

Neboisa Janjic

The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.

Method for generating aptamers with improved off-rates

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

Lung cancer biomarkers and uses thereof

The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).

Multiplexed analyses of test samples

The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art.

Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.

Multiaptamer target detection

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.

The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.

The present disclosure describes the isolation, identification and purification of aptamers having sufficiently high affinity and specificity to capture and immobilize intact sperm cells in the presence of female epithelial cells and other non-sperm semen components. The present disclosure also describes affinity-based methods for the detection of sperm cells in samples, including from forensic sample surrogates consisting of swab eluates containing a mixture of HeLa cells and sperm cells. The present disclosure describes methods for eluting sperm cell samples from swabs; methods for purifying sperm cells and methods for amplification and analysis of male DNA. The affinity-based system described herein is inexpensive, simple to use and easily implemented in forensic laboratories.

Method for purification and identification of sperm cells

Growing community of inventors

Boulder, CO, United States of America

Larry M Gold